Interleukin Genetics,Inc. (OTCMKTS:ILIU) Files An 8-K Regulation FD Disclosure

Interleukin Genetics,Inc. (OTCMKTS:ILIU) Files An 8-K Regulation FD Disclosure
ITEM 7.01 Regulation FD Disclosure

Story continues below

To the extent deemed necessary the information set forth in Item 8.01 is hereby incorporated by reference into this Item 7.01.

On July 24, 2017, Interleukin Genetics, Inc. (the “Company”) issued a press release announcing: (i) that it is seeking relief of its reporting obligations under Sections 12(g) and 15(d) of the Securities Act of 1934, (ii) several of members of its Board of Directors and Management team have resigned, and (iii) the adoption of a plan to wind-up and liquidate the Company.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

ITEM 9.01 Financial Statements and Exhibits
(1) The disclosures made in Form 8-K filed July 3, 2017 are hereby incorporated by reference to this report.
(2) The following Exhibit is filed with this report.
Exhibit 99.1 Press release dated July 24, 2017


INTERLEUKIN GENETICS INC Exhibit
EX-99.1 2 v471353_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1 Interleukin Genetics to Wind-Up and Pursue a Plan of Liquidation   Will begin process of delisting and deregistering   WALTHAM,…
To view the full exhibit click here

About Interleukin Genetics,Inc. (OTCMKTS:ILIU)

Interleukin Genetics, Inc. develops and markets genetic tests for chronic diseases and health-related conditions. The Company operates through the genetic test business segment. The Company’s products include PerioPredict genetic test and Inherent Health line of genetic tests. PerioPredict is a genetic risk test that analyzes genetic variations associated with inflammation and identifies individuals with a life-long predisposition to over-produce inflammation. PerioPredict identifies specific polymorphisms (genetic variations) in genes that regulate the production of interleukin-1 cytokines. PerioPredict identifies adults at increased risk for severe periodontal disease. The Company markets additional genetic tests through its Inherent Heath brand. Its additional genetic tests include weight management genetic test, bone health genetic test, heart health genetic test, nutritional needs genetic test and wellness select genetic test.

An ad to help with our costs